t
| Date | 21 Mar 2022 |
| Time | 10:44:34 |
| Category | Director/PDMR dealings |
| ID | 4453F |
Long Term Incentive Plan Option Grant
London, UK - 21 March 2022: Oxford Biomedica plc ("Oxford Biomedica" or the "Company") (LSE:OXB), a leading gene and cell therapy Group announces that on 18 March 2022 nil-cost share options over shares of 50 pence each in the Company were granted under the Oxford Biomedica 2015 Long Term Incentive Plan to Tim Kelly, Chief Executive Officer of Oxford Biomedica Solutions as part of the arrangements agreed in connection with its deal with Homology.
Mr Kelly has been granted: a restricted stock award over 35,256 shares which will vest in equal instalments on each of 10 March 2023, 10 March 2024, 10 March 2025 and 10 March 2026; a restricted stock award over 58,760 shares which will vest as to 25% in September 2022, 25% in March 2023 and 50% in September 2023; and a performance based award over 58,761 shares which will vest following the end of a three year performance period subject to the achievement of a revenue performance condition.
|
Name of individual |
Title |
Number of shares subject LTIP grant (restricted stock award) |
Total shares over which options are held |
Percentage of issued share capital under option |
|
Tim Kelly |
Chief Executive Officer, Oxford of Biomedical Solutions |
152,777 |
152,777 |
0.16% |
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
||||||||||||||
|
a) |
Name |
Tim Kelly |
|||||||||||||
|
2. |
Reason for the notification |
||||||||||||||
|
a) |
Position/status |
Chief Executive Officer of Oxford Biomedica Solutions
|
|||||||||||||
|
b) |
Initial notification/ amendment |
Initial Notification |
|||||||||||||
|
3. |
Details of the Issuer |
||||||||||||||
|
a) |
Name |
Oxford Biomedica plc |
|||||||||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
|||||||||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||||||||
|
a) |
Description of the financial instrument
Identification code |
Options over Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
|||||||||||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
|||||||||||||
|
c) |
Price(s) and volumes(s) |
|
|||||||||||||
|
d) |
Aggregated information Aggregate volume
Price
|
Awards granted over 152,777 shares in total
N/A
|
|||||||||||||
|
e) |
Date of the transaction |
2022-03-18 |
|||||||||||||
|
f) |
Place of the transaction |
Outside of trading venue |
|||||||||||||
-Ends-
|
For further information, please contact: |
|
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group. In January 2022, Oxford Biomedica announced that it was broadening its leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as a 20% owner. To date, Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Boehringer Ingelheim, Beam Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at www.oxb.com.